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S U M M A R Y
Background: An increased risk of cardiovascular complications has been found in those with community-
acquired pneumonia (CAP). Preliminary data suggest that pneumococcal pneumonia, more severe
pneumonia, older age, renal disease, hypoalbuminemia, and inpatient sliding scale insulin administra-
tion contribute to risk. The objective of this study was to ascertain additional factors inﬂuencing
cardiovascular events in CAP.
Methods: This investigation was a retrospective cohort study of inpatients with CAP. Outcomes
evaluated were development of a cardiovascular event during hospitalization, deﬁned as acute
pulmonary edema, cardiac arrhythmia, or myocardial infarction. Those with and without events were
compared across cardiovascular- and pneumonia-speciﬁc variables by logistic regression to ascertain
factors that independently increase risk or reduce risk.
Results: Of 3068 inpatients with pneumonia, 376 (12%) developed a cardiovascular event. Hyperlipid-
emia, more severe pneumonia, and Staphylococcus aureus or Klebsiella pneumoniae as etiologies were
associated with increased risk, while statin use was associated with decreased risk.
Conclusions: This study highlights variables in CAP patients that should make clinicians vigilant for the
development of cardiac complications. Additional research is needed to determine if statins attenuate
cardiac risk in CAP.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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While community-acquired pneumonia (CAP) may result in
morbidity and mortality as a direct function of an infectious agent’s
deleterious effects on the respiratory system, those with CAP are
known to develop additional complications extraneous to the lungs.1
These complications may not be directly related to the pathogen
itself, but are postulated to be due in part to the inﬂammatory
response that ensues.2 Among other sequelae, evidence has
suggested an increased risk of cardiovascular events, such as
myocardial infarction, in those with CAP.3,4 Preliminary data have
demonstrated that infection with the pneumococcus,5,6 older age, a
previous cardiac history, severe pneumonia,2,6 chronic kidney
disease, hypoalbuminemia,6 and sliding scale insulin administration
during a CAP episode7 may contribute to developing cardiac
incidents in CAP. In contrast, other reports have suggested improved
outcomes in general in the setting of CAP with medications
mitigating cardiovascular disease, such as statins and angiotensin
converting enzyme (ACE) inhibitors,8 but no study has evaluated* Corresponding author. Tel.: +1 502 852 1148; fax: +1 502 852 1147.
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medications. As a result, the objective of this study was to ascertain
additional risk factors or protective factors inﬂuencing cardiovascu-
lar events in CAP, including medications prescribed speciﬁcally for
cardiovascular diseases, and to clarify previously deﬁned risk factors
for such events.
2. Methods
2.1. Study design and population
This study was a secondary analysis of the Community-Acquired
Pneumonia Organization (CAPO) database on CAP, a multicenter,
retrospective, international cohort study of inpatients from 80
centers in 13 countries. Patients with a conﬁrmed diagnosis of CAP
were entered into the database from June 1, 2011 to November 12,
2012. Data procured for CAPO were collected on a case report form,
entered into a computer database, and then reviewed for quality
assurance before ﬁnal acceptance into the database. Institutional
review board evaluation was performed at each of the sites from
which patients were sampled. Informed consent was waived due to
the retrospective nature of this investigation.
Inclusion criteria were age 16 years and conﬁrmed CAP. CAP
was veriﬁed if a new inﬁltrate on chest X-ray was present with anyses. Published by Elsevier Ltd. All rights reserved.
Table 1
Distribution of cardiovascular events by category of eventa
Event n (%) Present on
admission
Developed
during
hospitalization
(n = 435) (n = 188) (n = 247)
New onset arrhythmia 179 (41) 70 (37) 109 (44)
New onset pulmonary
edema
127 (29) 64 (34) 63 (26)
Worsening of preexisting
arrhythmia
73 (17) 28 (15) 45 (18)
Myocardial infarction 56 (13) 26 (14) 30 (12)
a All values are given as number (n) of events by category (% of total events).
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ml, or >5% bands; new onset or increased cough; or temperature
37.8 8C or 35.6 8C. Patients were excluded if pneumonia
developed 48 h or more after admission. CAP severity was
ascertained by the Pneumonia Severity Index (PSI).9 Etiologic
organisms of pneumonia were discerned primarily by blood or
sputum culture. Some institutions performed urinary antigen
testing (Legionella pneumophila and Streptococcus pneumoniae),
PCR testing (Mycoplasma pneumoniae, Legionella pneumophila,
Chlamydia pneumoniae, and respiratory viruses), and sputum
culture on buffered charcoal yeast extract agar (BCYE) or direct
ﬂuorescent antibody staining of sputum for Legionella species.
2.2. Study deﬁnitions
A cardiovascular event was deﬁned as acute pulmonary edema,
new onset cardiac arrhythmia, exacerbation of a preexisting
arrhythmia, or myocardial infarction. All events were conﬁrmed by
an attending physician at the time they transpired and were
required to be documented in the medical records to be considered
present for this analysis. Pulmonary edema was diagnosed by a
combination of clinical exam ﬁndings (such as jugular venous
distension), radiologic evidence, and/or elevated brain natriuretic
peptide levels. For an arrhythmia to be considered exacerbated,
new clinical signs or symptoms, such as chest pain, dyspnea, or
cardiac arrest, had to accompany the arrhythmia and be deemed by
the treating physician to be due to the arrhythmia. Myocardial
infarction was veriﬁed by electrocardiogram aberrations and
elevated cardiac biomarkers including myocardial speciﬁc creatine
kinase and/or cardiac troponins. To be considered relevant to the
current episode of pneumonia, all cardiovascular events had to
transpire upon admission for CAP or at some time during the
concurrent hospitalization for CAP. If a patient developed more
than one cardiac incident during hospitalization, the case in
question was counted as a single cardiac event in analyzing the
primary outcome. Comorbidities, such as hyperlipidemia or
previous cardiac disease, were deﬁned as present if documented
in the medical records by a medical provider.
2.3. Study outcomes
The primary outcome assessed in this study was development
of a cardiovascular event during admission for CAP. Secondary
outcomes included in-hospital mortality and 28-day mortality, the
cumulative number of deaths from admission until 28 days after
admission, regardless if the patient was discharged from the
hospital. Categories of variables collected as potential confounders
of cardiovascular events and used in multivariate analyses were:
age, sex, history of cardiovascular disease prior to pneumonia
admission, history of atrial ﬁbrillation prior to admission, current
smoking status, family history of cardiac disease, use of
cardiovascular medicines (anticoagulants (heparin or warfarin),
aspirin, alternative antiplatelet agents (clopidogrel, ticlopidine),
beta-blockers, ACE inhibitors, or statins), genus and species of
infecting bacteria, initiation of empiric therapy within 8 h of
pneumonia diagnosis, empiric macrolide therapy during pneumo-
nia admission (erythromycin, clarithromycin, or azithromycin),
empiric quinolone therapy during pneumonia admission (moxi-
ﬂoxacin, levoﬂoxacin, ciproﬂoxacin, oﬂoxacin, gemiﬂoxacin, or
lomeﬂoxacin), albumin level on admission, pneumonia severity by
PSI, and presence of bacteremia related to pneumonia. For this
analysis, use of a medication was deﬁned as use during the current
hospitalization for pneumonia or use as an outpatient prior to
admission. Empiric antibiotic therapy was denoted as the
antibiotic regimen begun within the ﬁrst 48 h of admission before
an etiologic agent was identiﬁed.2.4. Statistical analyses
Chi-square or Fisher’s exact tests were used to compare
baseline categorical characteristics of those with and without
cardiovascular events, while the Mann–Whitney U-test was used
to compare continuous characteristics between the two groups.
To create a predictive model to evaluate variables signiﬁcantly
associated with cardiovascular events in hospitalized patients with
CAP, multivariable logistic regression models were employed.
Rather than eliminating patients with missing values for any
particular variable, we used bootstrapped additive imputation
models to create datasets with complete data for every patient. A
total of 20 imputed datasets were created to obtain the most valid
variance estimates. In each dataset, all variables were analyzed for
collinearity using variance inﬂation factor and tolerance statistics.
Next, these 20 datasets were each subjected to a purposeful
selection algorithm to create a ﬁnal best-ﬁt predictive logistic
regression model.10 The variables collected as potential confoun-
ders of cardiovascular events, as previously elucidated, were the
ones included in the purposeful selection algorithm. Brieﬂy, the
purposeful selection algorithm initially selects variables with
bivariate p-values of 0.25, and ﬁts a model based on backwards
elimination. Next, variables eliminated by backwards elimination
are further assessed for potential confounding along with the
remaining variables, and any included variable with a 15%
change in the regression coefﬁcient is replaced in the model.
Finally, variables initially excluded based on the bivariate analysis
are further assessed for confounding with the included variables
and are similarly added back to the model if the regression
coefﬁcients change by 15%. In this analysis, variables remaining
in the purposeful selection of each of the 20 datasets were noted,
and any variables remaining in more than 50% of the purposefully
selected models were included in a ﬁnal logistic regression model.
R version 2.15.111 and SAS version 9.3 (SAS Inc, Cary, NC) were
used for all analyses. The Hmisc package was used for multiple
imputation following accepted procedures.12 Except as speciﬁed
previously in the initial selection of variables in the purposeful
selection algorithm, p-values 0.05 were considered signiﬁcant.
3. Results
Of 3068 patients with CAP, 376 (12%) presented with at least one
cardiovascular event upon admission or subsequently developed an
event during hospitalization. However, in total, 435 events occurred,
as some patients had more than one cardiovascular incident during
hospitalization. The most common event to transpire was exacer-
bation of a previously diagnosed arrhythmia (Table 1). Those with a
cardiac complication were more likely to be older and to have had a
preexisting cardiac history, atrial ﬁbrillation, hypertension, or
hyperlipidemia. Furthermore, they were more likely to have been
administered empiric macrolide therapy or to have been prescribed
aspirin or another antiplatelet, beta-blockers, or ACE inhibitors as a
Table 2
Baseline patient characteristics in those with and without a cardiovascular event
during admissiona
Variable Cardiovascular
event
n (%)
No cardiovascular
event
n (%)
p-Value
(n = 376) (n = 2692)
Demographics
Age, years, median (IQR) 78 (21) 64 (33) <0.001
Male sex 217 (58) 1572 (58) 0.823
Comorbidities
Cardiovascular disease 49 (13) 180 (7) <0.001
Atrial ﬁbrillation 66 (18) 176 (7) <0.001
Arterial hypertension 139 (37) 706 (26) <0.001
Hyperlipidemia 61 (16) 283 (11) 0.002
Current smoking 55 (15) 520 (21) 0.006
Family history of CAD 28 (7) 167 (6) 0.366
Albumin, mg/dl,
median (IQR)
3.2 (0.7) 3.2 (0.9) 0.390
Cardiovascular medicine use
Warfarin 20 (5) 108 (4) 0.269
Heparin 7 (2) 28 (1) 0.180
Aspirin 77 (20) 345 (13) <0.001
Antiplatelet therapy 22 (6) 80 (3) 0.008
Beta-blocker therapy 70 (19) 325 (12) 0.001
ACE inhibitor therapy 66 (18) 370 (14) 0.058
Statin therapy 43 (11) 294 (11) 0.792
Pneumonia etiology and bacteremia
Streptococcus pneumoniae 48 (13) 427 (16) 0.128
Moraxella catarrhalis 0 (0) 7 (0) 1.000
Haemophilus inﬂuenzae 6 (2) 28 (1) 0.298
Staphylococcus aureus 20 (5) 74 (3) 0.010
Escherichia coli 6 (2) 19 (1) 0.114
Klebsiella pneumoniae 7 (2) 12 (0) 0.005
Legionella pneumophila 3 (1) 39 (1) 0.470
Pseudomonas aeruginosa 5 (1) 32 (1) 0.800
Bacteremia 46 (12) 315 (12) 0.733
Antibiotic therapy and severity of disease
Therapy within 8 h 257 (81) 827 (82) 0.828
Empiric macrolide
therapy
302 (80) 2027 (75) 0.034
Empiric quinolone
therapy
140 (41) 827 (36) 0.102
PSI, median (IQR) 124 (51) 93 (60) <0.001
CAD, coronary artery disease; ACE, angiotensin converting enzyme; IQR,
interquartile range; PSI, Pneumonia Severity Index.
a All values are given as number (%) unless otherwise speciﬁed.
Table 3
Results of the multivariate logistic regression analysisa
Variable Odds ratio (95% CI) p-Value
Age 1.01 (1.00–1.02) 0.137
Male gender 0.84 (0.66–1.08) 0.177
Hyperlipidemia 2.01 (1.33–3.05) 0.001
Statin therapy 0.52 (0.33–0.84) 0.007
Staphylococcus aureus 1.61 (1.02–2.86) 0.050
Klebsiella pneumoniae 2.95 (1.05–8.68) 0.050
Empiric macrolide therapy 0.81 (0.64–1.03) 0.089
PSI 1.02 (1.01–1.02) <0.001
95% CI, 95% conﬁdence interval; PSI, Pneumonia Severity Index.
a These variables represent the ones retained in the ﬁnal logistic regression
model after the purposeful selection algorithm was executed.
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pneumoniae were more likely pathogens in this group, and
pneumonia severity was greater at baseline in those with an event
(Table 2).
After the purposeful selection algorithm was executed on all of
the variables from Table 2, those remaining in the ﬁnal best-ﬁt
logistic regression model included age, male gender, hyperlipid-
emia, statin therapy, S. aureus or K. pneumoniae as etiologies of CAP,
empiric macrolide therapy, and pneumonia severity. However,
only hyperlipidemia, greater pneumonia severity, and S. aureus or
K. pneumoniae as etiologies of CAP remained as signiﬁcant
predictors of a cardiovascular event, while statin therapy wasTable 4
The most common cardiovascular events by risk factor found to be statistically signiﬁc
Cardiovascular event
Risk factor New onset arrhythmia, n (%) Pulmonary ed
Hyperlipidemia (n = 72) 29 (40) 19 (26) 
Staphylococcus aureus (n = 24) 11 (46) 5 (21) 
Klebsiella pneumoniae (n = 11) 4 (36) 1 (9) 
PSI class IV or V (n = 364) 146 (40) 113 (31) 
PSI, Pneumonia Severity Index.
a All values are number of a given cardiovascular event per risk factor (% of total evassociated with a lower risk of an event (Table 3). For the risk
factors found to be statistically signiﬁcant in the ﬁnal regression
model, the distribution by type of cardiovascular incident for each
factor is shown in Table 4.
Finally, those patients developing cardiovascular incidents
during admission were signiﬁcantly more likely to die during
hospitalization or at 28 days after admission. During admission,
28% of the event group died compared to 8% of the non-
cardiovascular event group (p < 0.001). Cumulatively at 28 days
from admission, 36% of the total cardiovascular event group died
compared to 10% in the comparison group (p < 0.001).
4. Discussion
The present study demonstrated an increased risk of cardio-
vascular sequelae in the context of CAP in those patients who had a
history of hyperlipidemia, had a greater pneumonia severity, or
had S. aureus or K. pneumoniae as etiologies of pneumonia. In
addition, this study illustrated a trend for a greater risk in those
who were older. Those patients having cardiac complications were
more likely to die during hospitalization or at 28 days. In contrast,
this analysis found statins to be protective with regards to
developing cardiac events, while suggesting a trend for less risk
with empiric macrolides. However, additional medications,
including those that have effects on the cardiovascular system
such as beta-blockers and ACE inhibitors, were not demonstrated
to inﬂuence cardiac sequelae. These results are important because
they suggest that certain at-risk patients (those with hyperlipid-
emia, higher pneumonia severity, S. aureus or K. pneumoniae, and
older age) deserve vigilance on the part of clinicians for developing
cardiac complications in the setting of CAP and likely require
additional cardiac monitoring to recognize these events early and
intervene appropriately. These ﬁndings also suggest medications
(statins) that should be further investigated as agents to attenuate
events. To our knowledge, this is the ﬁrst study to delineate
hyperlipidemia, S. aureus or K. pneumoniae as etiologies, or statin
use as potential mediators of cardiovascular events in CAP.
The elevated cardiovascular risk with hyperlipidemia elaborat-
ed in the current study is thought to be due to the association of
hyperlipidemia with atherosclerotic plaque that may becomeant in the ﬁnal regression modela
ema, n (%) Worsening arrhythmia, n (%) Myocardial infarction, n (%)
6 (8) 18 (25)
4 (17) 4 (17)
2 (18) 4 (36)
53 (15) 52 (14)
ents for that risk factor).
A.T. Grifﬁn et al. / International Journal of Infectious Diseases 17 (2013) e1125–e1129e1128unstable during infection.13 Furthermore, stabilization of this
plaque by statin therapy,14 or reduction of the subsequent cytokine
storm by these medicines,15 may have contributed to the
attenuated risk in those administered statins.
The increased event rate seen with more severe pneumonia in
this study, though not robust, and the increased event rate
illustrated with S. aureus and K. pneumoniae, are likely explained by
the extreme cytokine cascade that ensues in these settings. This
inﬂammation may contribute directly to plaque destabilization,13
progression of atherosclerosis as a result of prolonged aberrations
in lipoprotein proﬁles,16 and predisposition to arrhythmias.17
Despite the association of macrolide antibiotics with QTc
prolongation,18 they were not linked to cardiac events in this
study, and in fact, appeared to be associated with a decreased risk.
It is postulated that the potential anti-inﬂammatory properties of
macrolides in respiratory infection19 and their activity against
atypical bacteria that may comprise coronary plaques,20 may
explain the trend for lower cardiac incidents seen with such
therapy.
The results of the current study are concordant with past
evidence that has found elevated cardiac risk in the setting of CAP
related to increased age and greater pneumonia severity.2,6
However, in contrast to previous literature that has found an
overt cardiac history to be a risk for events,2,6 the current study
only found a common accompaniment of prior cardiovascular
disease, hyperlipidemia, to be a risk, and as a result, indirectly
replicates the ﬁndings of increased cardiovascular occurrences and
a prior cardiac history. It is plausible that hyperlipidemia and
atherosclerotic plaque are the principle determinants of cardiac
events in the context of CAP in those with prior cardiac histories.
While the current analysis did not ﬁnd the pneumococcus to be a
risk for cardiac sequelae like previous reports,5,6 related virulent
pathogens, including K. pneumoniae and S. aureus, were found to be
risks. It may be that if the extensive list of pathogens included in
the current investigation had been included in other analyses, the
association in these past studies with the pneumococcus and
cardiac complications may have become attenuated.
The current study is the ﬁrst to our knowledge to illustrate the
protective effects of statins in relation to cardiac events and CAP.
Given that the level of evidence we present is observational, we
could not eliminate the contribution of confounders such as the
healthy user effect that may explain these results with statins.
However, statins have also been shown to reduce morbidity and
mortality in general in the setting of CAP.8 The potential reduction
of cardiac events seen in the current analysis associated with
statins could be one of the mechanisms for the reduced morbidity
and mortality in pneumonia elucidated in other studies addressing
CAP and statins.8 Further supporting the results of the current
study related to statins is basic science data illustrating attenua-
tion of cardiovascular system dysfunction with statin administra-
tion in acute lung injury created by endotoxin.21 The suggestion of
beneﬁcial cardiac effects with macrolides is also novel, but is
preliminary and difﬁcult to interpret. Recent studies with
macrolides illustrating both increased cardiac sequelae, particu-
larly arrythmias,22,23 and lack of increased sequelae exist.24 One
putative explanation for these disparate results in the literature
and the ﬁndings in the present study that differ from the former
two studies, is that macrolides may have differential effects
depending on the type of cardiac event. Events with a prominent
inﬂammatory component like myocardial infarction13 may be
reduced, while events linked to aberrations in the cardiac
conduction system may be increased. With the current analysis,
we were not able to unravel this postulated bidirectional cardiac
effect of macrolides.
The results of the current analysis are generalizable to the
general adult CAP population given the multiple centers includedand few exclusion criteria employed. The diverse population under
study in CAPO, as well as the rigorous data collection process and
statistical analysis in this study, are also clear strengths.
Furthermore, the inclusion of multiple potential variables affecting
cardiac events, such as cardiovascular medications, macrolide use,
and additional pathogens that have not been included in other
studies, is a strength.
A limitation, however, is the retrospective design; thus, given
the lack of randomization to medications like statins, causation
cannot be inferred, leaving explanations such as the healthy user
bias to be considered. In addition, recently approved cardiovas-
cular medications, such as dabigatran and rivaroxaban, angioten-
sin receptor blockers, anticoagulants other than warfarin and
heparin, and potential modulators of events like sliding scale
insulin,7 were not evaluated, as these variables were not
previously procured in the CAPO database. Furthermore, factors
affecting volume status and resultant pulmonary edema in
particular, such as acute kidney injury and degree of volume
resuscitation required for those in severe sepsis, were also not
evaluated for similar reasons. Finally, while speciﬁc criteria for the
diagnosis of cardiac events were utilized in most instances, the
diagnosis of a cardiac event was ultimately left to the treating
physician and conﬁrmed retrospectively.
Further investigation is needed to replicate and extend these
results. In particular, prospective, observational studies concerning
the relationship of macrolides to cardiac disease are required given
the present ﬁndings and the controversy that exists in the
literature related to these antibiotics. Future study should
endeavor to discriminate risks and beneﬁts of macrolides in
relation to the category of cardiac event. Given that ample
observational evidence has illustrated the beneﬁt of statins in the
context of pneumonia in general and that the current study
showed a reduced risk of cardiac events in those patients on
statins, a randomized controlled trial investigating statin therapy
prescription at the time of pneumonia diagnosis is warranted.
In summary, we found a previous diagnosis of hyperlipidemia,
greater pneumonia severity, and S. aureus or K. pneumoniae as
causes of pneumonia to be risks for cardiac events in CAP. Patients
with these complications were more likely to die during
hospitalization or at 28 days. In contrast, previous or current
use of statins was protective, while there was a trend for less risk
with macrolides. These results are important because they suggest
patient factors of which clinicians should be cognizant in order to
identify cardiac events early in at-risk patients and intervene in a
timely fashion. Telemetry or frequent ECG monitoring seems
particularly prudent in those harboring multiple risk factors.
Finally, these ﬁndings argue for further study on statins and
macrolides concerning cardiac events in the setting of pneumonia.
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